Suppression of KRAS did not reduce macropinocytosis in any of the seven KRASG12R mutant pancreatic cancer cell lines investigated in their study, and KRASG12R uniquely failed to stimulate macropinocytosis in three model systems (rat intestinal epithelial cells RIE-1, mouse fibroblasts NIH/3T3 and hTERT-immortalized human pancreatic duct-derived epithelial cells), similar to KRASG12D or KRASG12V20. This evidence concerns the gene KRAS and familial pancreatic carcinoma.